Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, IONIS PHARMACEUTICALS, INC. reported revenue of $944M, up 33.8% year over year. Operating margin was -40.4% and net margin -40.4%, on a free-cash-flow margin of -33.9% with capital expenditure at 5.5% of revenue. Every figure is computed directly from IONS's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $944M | -40.4% | -40.4% |
| FY2024 | $705M | -67.4% | -64.4% |
| FY2023 | $788M | -44.9% | -46.5% |
| FY2022 | $587M | -69.8% | -45.9% |
| FY2021 | $810M | -3.7% | -3.5% |
How does IONS compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.